Biolase, Inc.
BIOL
BIOL was delisted on the 18th of June, 2024.
12 hedge funds and large institutions have $199K invested in Biolase, Inc. in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 17 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
36% less capital invested
Capital invested by funds: $312K → $199K (-$113K)
52% less funds holding
Funds holding: 25 → 12 (-13)
76% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$271K |
| 2 |
BlackRock
New York
|
+$126K |
| 3 |
ZF
Zhang Financial
Portage,
Michigan
|
+$55.1K |
| 4 |
Walleye Capital
New York
|
+$14.4K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.15K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$67K |
| 2 |
APP
Avantax Planning Partners
Dubuque,
Iowa
|
-$38.5K |
| 3 |
Millennium Management
New York
|
-$28.8K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$11.4K |
| 5 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$11K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Northern Trust
Chicago,
Illinois
| – | -$2.12K | -300 | Closed |
|
27
State Street
Boston,
Massachusetts
| – | -$1.23K | -174 | Closed |
|
|
BBA
28
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
| – | -$599 | -109 | Closed |
|
29
Fidelity Investments
Boston,
Massachusetts
| – | -$2 | – | – |
|
BIOL Hedge Fund Activity: Q3 2023 in Review
12 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q3 2023, worth a combined $199K — down 36% from $312K a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of BIOL and 4 opened new positions — a net loss of 13 holders — while 1 trimmed existing stakes and 7 added.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $271K. The largest seller was Acadian Asset Management, exiting entirely with an estimated $67K sold.
- 12 institutional investors held Biolase, Inc. (BIOL) as of Q3 2023, down from 25 in Q2 2023.
- Funds reported $199K of Biolase, Inc. stock for Q3 2023, down 36% quarter-over-quarter.
- 4 funds opened new Biolase, Inc. positions in Q3 2023 and 17 closed out, a net change of -13 holders.
- The largest Biolase, Inc. buyer in Q3 2023 was Anson Funds Management, an estimated $271K added.
- The largest Biolase, Inc. seller in Q3 2023 was Acadian Asset Management, an estimated $67K sold.
Based on aggregated 13F filings for Q3 2023.